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Abstract
Background—Clinical and experimental studies have traditionally focused on understanding the
mechanisms for why a heart fails. We hypothesize that the pathways involved with myocardial
recovery are not simply the reverse of those that cause heart failure. However, determining when
and how a decompensated heart can recover remains unknown.
Methods—Male C57BL/6 mice underwent minimally invasive aortic banding for 3, 4, or 6
weeks with or without subsequent band removal for one week (debanding). Physiologic and
genomic characterization was performed with intracardiac pressure-volume recordings, rt-PCR,
and microarray analysis.
Results—Heart weight/body weight ratios and PV loops demonstrated a transition from
compensated left ventricular hypertrophy to decompensated heart failure between 3 and 4 weeks.
Pressure-relief afforded by debanding allowed functional recovery and normalization of LVH after
both 3 and 4, but not 6 weeks of banding. Whole genome microarrays demonstrated 397 genes
differentially expressed in recovered hearts, 250 genes differentially expressed in the
nonrecoverable (6 week) hearts, and only 10 genes shared by both processes. In particular, altered
expression patterns of apoptotic and metalloproteinase genes correlated with the heart's ability to
functionally recover.
Conclusions—This clinically-relevant model (1) allows us to temporally and mechanistically
characterize the failing heart, (2) demonstrates a unique genomic signature that may predict when
a failing heart can recover following pressure relief, and (3) will prove useful as a template for
testing therapeutic strategies aimed at recovery of the failing heart.
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Heart failure (HF) remains a highly morbid and increasingly prevalent disease. A
fundamental weakness in impacting this disease is a translational disconnect. That is, the
majority of experimental efforts center on preventing development or halting progression of
HF, whereas clinicians are challenged by caring for patients with existing, and often,
advanced disease. While many basic studies have examined factors involved with
remodeling [1–3], few have focused exclusively on reverse remodeling. Several reversible
animal models of left ventricular hypertrophy (LVH) and HF exist including anemia,
hyperthyroidism, aortocaval fistulae, and infusion of angiotensin II and isoproterenol [4–7].
Yet, these models do not fully account for the important link between hypertension and HF
that is supported epidemiologically and clinically [8]. As such, we and others are
particularly interested in the changes that occur with pressure-overload. Although the
transverse aortic constriction (TAC) method is routinely used to create LVH, the idea of
removing the mechanical burden by removal of the constrictive band, albeit conceptually
attractive, has not widely been examined. A murine study demonstrated normalization of
atrial natriuretic peptide and collagen I and II after relief of pressure-induced LVH [9].
Distinct genes associated with regression were also identified in a rat model of pressure-
relief [10]. Similarly, we have previously reported a technique whereby removal of a
previously placed aortic constrictive band can reverse murine left ventricular hypertrophy
[11, 12].
Unfortunately, existing models of LVH regression do not account for the variability of
physiologic function that we encounter in patients with HF. An emerging area for the study
of reverse remodeling in failing human hearts is derived from paired LV samples taken from
patients undergoing left ventricular assist device (LVAD) placement and subsequent heart
transplantation [13, 14]. Although serial examination of a single patient's LV tissue
represents a unique opportunity, its use as a widespread mechanistic tool for reverse
remodeling is limited by small numbers, heterogeneity of tissues, and diversity of patient
disease. Importantly, LVADs are typically used in the most advanced forms of HF, thus
excluding the majority of patients that have treatable HF. Thus, many questions regarding
cardiac recovery remain including, what makes some hearts recover when others continue to
fail, and is there a point when a failing heart no longer has a chance to recover. Herein, we
extend our previous work with regression of murine LVH to provide a unique approach for
studying myocardial failure and recovery that allows us to physiologically and genomically
characterize cardiac recovery.
Material and Methods
Surgical model and experimental design
In accordance with an institutionally approved IACUC protocol, minimally-invasive
transverse arch banding and debanding were performed in 10-week-old C57BL6 male mice
(Charles River Laboratories, Wilmington, MA) as previously described [12]. In brief,
animals were anesthetized using inhaled isoflurane by facemask. A midline neck incision
was used to approach the anterior mediastinum. The transverse arch was identified and a
constrictive band was placed and tightened to the approximate diameter of a 27 gauge
needle. Appropriate placement of the band was verified by evaluation of carotid artery
dopplers both before and after placement of the aortic band. Adequate banding was accepted
when the Doppler velocity ratio doubled from right to left carotid arteries.
Animals were randomly assigned to three Banded groups: 3 week Band, 4 week Band, and 6
week Band (n=5 per group). In addition to the 3 Banded groups, animals were randomly
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assigned to 3 Debanded groups: 3 week Band/1 week Deband, 4 week Band/1 week
Deband, and 6 week Band/1 week Deband (n=5 per group). Animals in the Deband groups
had initial procedures identical to those for the Band animals. At the designated week, the
aortic band was removed, referred to as Debanded. Deband animals were sacrificed one
week following the deband procedure for all evaluations (Figure 1). Prior to any
experimentation the mice were housed in the same cubicle in a DLAM facility with 12 hour
light cycling and ad libitum access to water and chow.
Cardiac function analysis
Immediately prior to sacrifice, animals in all 6 groups (3 week Band, 4 week Band, 6 week
Band, 3 week Band/1 week Deband, 4 week Band/1 week Deband, and 6 week Band/1week
Deband) underwent pressure-volume loop analysis in a closed-chest method with a 1 Fr
Millar Catheter PVR-1045 (Millar Instruments, Houston, TX) as previously described [15].
Pressure-volume loops were recorded using Labview 7.1 Software (National Instruments,
Austin, TX) and analyzed with PVAN (Millar Instruments).
RNA extraction and microarray analysis
At time of animal sacrifice, hearts were rapidly excised and the left ventricular apices were
sectioned and flash frozen in liquid nitrogen for gene array analysis. Total RNA was
extracted from murine cardiac tissue using the Qiagen RNeasy Minikit (Quiagen, Valencia,
CA) in accordance with the manufacturer's instructions including the optional DNase step.
RNA integrity was verified by assay on an Agilent BioAnalyzer 2100. Five hundred
nanograms of total RNA was labeled with Cyanine-5 CTP in a T-7 transcription reaction
using the Agilent Low Input Linear RNA Amplification/Labeling System. Labeled cRNA
from test samples was hybridized to Agilent G4122F Mouse Whole Genome 4 × 44K
microarray slides in the presence of equimolar concentrations of Cyanine-3 CTP labeled
Human Universal Reference RNA [16].
Realtime PCR
Extracted RNA was converted to cDNA using a High-Capacity cDNA Archive kit (Applied
Biosystems International, Foster City, CA). Expressed genes were amplified using TaqMan
polymerase, TaqMan-matched probes and primers (ABI). Expressed genes evaluated
included myosin heavy chain (b-MHC), brain natriuretic peptide (BNP), skeletal muscle
alpha1-actin (ACTA-1), collagen type 1 alpha 1 (COL1a1), B-cell leukemia/lymphoma 2
(Bcl2), Bcl2-associated X protein (BAX), TNF receptor-associated factor 6 (TRAF6),
bacloviral IAP repeat-containing 3 (BIRC3), tissue inhibitor of metalloproteinase 1
(TIMP1), and matrix metalloproteinase 9 (MMP9). 18s rRNA served as an internal control.
Real-time PCR was performed using an ABI 7900 instrument (Applied Biosystems).
Relative quantification results were obtained using SDS 2.2.2 software (Applied
Biosystems).
Statistical methods
All physiologic data are presented as mean +/− standard error (SE) except where noted.
Real-time PCR data were log transformed prior to comparison. All comparisons of
physiologic data were performed using 2-tailed, type 3 or type 1 t-tests using the statistical
software Prism 4 (Graph Pad, San Diego, CA). Statistical significance was accepted within
the 95% confidence interval.
Microarray data (n=4/experimental group) were loess normalized [17] and probes were
filtered for features having a normalized intensity of < 30 aFU in either channel, then a
probe was removed if <70% of the data were present across all samples. Missing data points
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were imputed using the k nearest-neighbors algorithm (k = 3). Duplicate probes were
collapsed to a single datapoint representing the mean expression ratio of each duplicate
probe. 30,752 probes passed these filters, and were subsequently used for analysis. Scripts
written in the R Statistical Language and Environment (“R”; Version 2.2.1, build r36812,
release date 2005-12-20.) and Perl (ActiveState Perl 5.8.1, build 807, release date
2003-11-6) were used to standardize (μ = 0, σ=1) the data set.
Lists of differentially expressed genes were identified using the statistical analysis of
microarray algorithm (“SAM”, Version 2.21, release date 2005-8-24) [18–20]. Analysis was
performed with a typical false discovery rate of 10%, a combination of heteroscedastic
Student's T-test and mean fold change expression criteria (p value < 0.05, absolute mean
fold change (MFC) > 1.3), and custom R scripts written in our laboratory. Unsupervised,
semi-supervised, and supervised clustering analysis was performed on gene lists essentially
as described using Cluster (Version 2.11, http://rana.lbl.gov/EisenSoftware.htm) [21].
Heatmaps of cluster analyses were visualized with JavaTreeView (Version 1.0.12, release
date 2005-3-14; http://sourceforge.net/projects/jtreeview/). High-level pathway analysis was
performed with the Molecular Signatures Database [22].
Results
Physiologic Characteristics of Progression to Hypertrophic Heart Failure and Recovery
In order to standardize pressure loading and unloading within our model, carotid artery
Doppler velocities were used to verify adequate constriction and relief of transverse arch
banding and debanding, respectively. As previously observed [11, 12], banding increased
the right-to-left carotid velocity ratios. Doppler analysis prior to debanding demonstrated
consistent elevation in these gradients (i.e. the band did not slip). Furthermore, after band
removal, the right-to-left ratios decreased to normal levels (data not shown). The
normalization in gradients suggests enhanced flow through the aortic arch and subsequent
relief of pressure-overload on the mouse heart.
We next sought to determine a time-course relating duration of pressure-overload and extent
of hypertrophy with the ability to recover myocardial function following pressure-relief.
Myocardial mass as measured by HW/BW ratios fell significantly following debanding at 3
weeks and at 4 weeks, but did not decrease significantly after pressure unloading at 6 weeks
(Figure 2A). Functionally, as assessed by intraventricular pressure-volume measurements, 3
weeks of banding resulted in cardiac function that was equivalent to the level of an age-
matched mouse without prior surgery. More prolonged banding, however, resulted in
functional decline that was only reversible after 4 weeks of banding, but not after 6 weeks
(Figure 2B). Compared to animals banded for 3 weeks, the ejection fraction of animals
banded for 4 weeks dropped by over 20%. This level of dysfunction continued in 6 week
banded animals. Importantly, mice banded for 4 weeks that were subsequently debanded
were able to normalize their ejection fraction whereas those animals banded for 6 weeks
were unable to recover their function following pressure relief. Left ventricular pressure
volume loops qualitatively characterized these changes. Mice banded for 4 weeks had an
expected shift up and to the right, suggesting both pressure and volume overload. This
relationship was reversed with debanding. Furthermore, mice banded for 6 weeks had
profound increases in ventricular volume that was not able to be reversed with pressure
unloading. Summarily, the physiologic assessments of our experimental groups allow us to
designate 3 distinct groups based on when the animals were debanded: compensated (3
weeks), decompensated but recoverable (4 weeks), and decompensated but unrecoverable (6
weeks).
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To further assess the time-dependent biologic effects of pressure-overload and subsequent
relief, real-time PCR was performed in LV apical samples for hypertrophic and fibrotic gene
markers (Figure 3). As expected, β-myosin heavy chain expression sequentially increased
with prolonged pressure overload and decompensated heart failure and dropped with
pressure-relief afforded by debanding. A similar trend was observed with skeletal muscle
alpha1-actin. Brain natriuretic peptide expression was elevated after 3 and 4 weeks of
banding compared to its respective deband counterparts. But by 6 weeks of banding, levels
had fallen significantly. While this latter observation is perhaps not expected, one could
speculate that the left ventricle has reached maximal stretch in the dilated and failing 6 week
heart, and thus the stimulus for BNP transcription subsequently decreased [23]. Finally,
collagen type 1α1 transcription, a marker of the fibrotic process, increased during the
progression phase of pressure-overload by 6 weeks, and expectantly decreased after
debanding at each respective time point.
Pressure Relief Results in Distinct Genomic Patterns Dependent Upon Functional Phase
Prior to Ventricular Unloading
Our global hypothesis states that pressure-relief results in a gene expression pattern that is
not simply the reverse of those factors causing hypertrophy, but rather a unique signature. In
order to test this notion, we compared gene expression profiles between the physiologically
distinct groups described above. We first examined genomic expression patterns within the
individual cohorts. As demonstrated in the Venn diagrams in Figure 4A and 4B, there was
little overlap in gene expression between different stages of progression or regression of
heart failure. Development of LVH and HF with pressure overload demonstrated distinct
genomic profiles between from compensated LVH to decompensated LVH (3 weeks
banding to 4 weeks banding), decompensated LVH to terminally failed hearts (4 weeks
banding to 6 weeks banding), and compensated LVH to terminally failed hearts (3 weeks
banding to 6 weeks banding). While others have demonstrated similar findings [24], we
extend this paradigm to identify genomic differences in the process of regression. Indeed,
distinct patterns were also noted with individual stages of regression (Figure 4B). For
example, the genes expressed during the recovery of compensated LVH (3 week debanded
mice) were markedly different than those expressed with recovery from decompensated
hearts (4 week debanded mice) or failing hearts after pressure relief (6 week debanded
mice). The fact that 52 genes overlapped in the three week versus 4 and 6 week debanded
groups suggests some similarities in gene expression in the failing hearts with pressure
unloading.
We next sought to link the physiologic process of recovery with genomic patterning. We
therefore analyzed differences in gene expression between compensated hearts that
regressed their hypertrophy (3 week band and 3 week deband), decompensated hearts that
regained their function (4 week band and deband), and decompensated hearts that were
terminally failing (6 week band and deband group pairs). Using a p-value <0.05 and mean
fold change of > 1.3 strategy for the selection of differentially expressed genes, we
identified a total of 1,017 genes (Figure 4C). Of these, only 28 (2.8%) of these genes
overlapped between any 2 groups, and no genes were found to be common to all three.
These data suggest that the physiologic phenotype of recovery versus persistent failure is
associated with an independent genomic pattern that is dependent upon the functional phase
of cardiac hypertrophy prior to ventricular unloading.
Cluster analysis was then performed on the 3 banded groups, and separately on the 3
debanded groups. As depicted in Figure 5, the heat maps demonstrate tight clustering within
and between the experimental groups. To further delineate the genomic pathways and
transcription factors that regulate specific physiologic stages of hypertrophy and recovery,
genes specifically upregulated (i.e. 4 wk Up) or downregulated (i.e. 4 wk Down) were run
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through the Molecular Signatures Database [22]. Results for the banded groups,
representative of hypertrophy progression, are listed in Figure 5A. Results for the debanded
groups, or stages of hypertrophic recovery, are listed in Figure 5B.
Gross inspection of transcription factor targets reveals a recurrent role for the transcription
factor nuclear factor kappa B (NF-κB) in both the remodeling and recovery process. We and
others have previously implicated this signaling intermediate as important in hypertrophy
and heart failure [15, 25–28]. As such, we examined several NF-κB-dependent factors that
could offer mechanistic insight as to the process of pressure overload and relief. We focused
on transcription related to 2 processes – apoptosis and matrix turnover (Figure 6). Although
we did not observe differences in expression of the pro-apoptotic molecules, TRAF6 and
Bax (data not shown), the anti-apoptotic genes Birc3 and Bcl2 (albeit a trend, rather than
significant) were underexpressed in failing hearts that were banded for 6 weeks. Although
not significantly different, banding – in the early phases – increased Birc3 and Bcl2
expression that subsequently decreased with pressure relief. Expression of remodeling
molecules TIMP-1 and MMP-9 appear to see-saw with pressure overload and subsequent
relief. Interestingly, the failing and unrecoverable hearts (6 week banded) had markedly less
MMP-9 compared to those animals banded for 3 or 4 weeks.
Discussion
The current data support our global hypothesis that the mechanisms of myocardial recovery
are not simply the reverse of those that cause its failure. This line of investigation was
initially charged by a report that demonstrated independent gene expression with reversal of
isoproteronol-induced LVH [29]. When we first introduced this murine model of banding
and debanding, our focus was likewise on the reversal of left ventricular hypertrophy [12].
Indeed, several other groups have also examined LVH with pressure-relief following aortic
banding, both structurally and genomically [9, 10]. In turn, we have subsequently
demonstrated that the reversal of LVH with pressure-relief is associated with an independent
genomic signature as well as changes in markers of fibrosis [11, 13]. All of our previous
studies were performed with mice that were banded for 4 weeks prior to pressure-relief.
When we looked closely at our functional data, we noticed that these mice not only had
hypertrophy, but that they had decreased their ejection fraction [11]. To date, the literature
related to reversal of hypertrophy with pressure unloading has used limited timepoints of
loading. Our observation led us to predict that the length of pressure overload (banding)
determines the ability of that heart to regress. Although this was a conceptually intuitive
hypothesis, the three distinct patterns of reversal had not previously been demonstrated.
Although the individual components of this model system are not novel, we believe that
linking the functional groups with their genomic signature provides an innovative method
for studying the mechanisms associated with the recovery of the failing heart. We have
previously used echocardiography to define our subgroups [11, 12]. Although more labor
intensive, we utilized pressure-volume loops in the present study to obtain more sensitive
measures of function. These measurements allow us to establish 3 separate phases of
recovery (Figure 7): regression from compensated hypertrophy, recovery from
decompensated hypertrophy, and the terminally failing heart. Imbedded within this construct
is the identification of a point of no return. Our data suggests that after 4 weeks of banding,
the hearts enter a period of decompensation that is not, at least within our time interval,
recoverable.
In our previous reports, we demonstrated some of the histologic and molecular markers
associated with regression of hypertrophy [11, 12]. Although the hearts regain normal
structure and function with pressure-relief (3 and 4 week debanded animals), we cannot
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claim that they are genomically “normal.” As demonstrated simply in the Venn diagram, the
genomic patterns of unloading were different between each subgroup. These observations
will propel more detailed studies focusing on timing and better understanding of the
recovered state. For example, in this study, we detail the effects of debanding for each phase
only 1 week beyond each time point. In either direction (progression/regression), we are
likely witnessing a continuum of change as the heart both negatively and positively
remodels. Quite possibly, a more prolonged period of recovery would provide different
structural and genomic patterns. For example, would the 6-week animals show evidence of
reversal if we had given them a longer period of debanding? A previous study that banded
animals for 8 weeks and followed them after debanding for 6 weeks observed no resolution
of LV mass or fractional shortening [9]. We chose to organize the array around the 1 week
time point because our preliminary data indicated that the effective physiologic and
structural reversal of LVH was nearly complete at this time (and far-enough away from the
surgical procedure), despite differences in gene expression. Furthermore, we wished to
create a model that was a 3–6 week model rather than a 6–12 week model, allowing a more
practical approach for high throughput experiments. Finally, we acknowledge that this is a
model that relieves acute pressure overload. Thus, parallels to the insidious pressure-
overload that occurs with typical human aortic stenosis or hypertrophic heart failure, and its
subsequent reversal with aortic valve replacement or left ventricular assist devices, can only
be inferred.
The microarray data provide several pathways and transcription factor targets as well as a
long list of candidates of genes involved with reverse remodeling. We have a particular
interest in NF-κB biology and were intrigued with the high placement of this transcription
factor implicated within of our gene lists. Metalloproteinases and apoptotic-related genes are
clearly important in the remodeling process. Thus, we screened several related NF-κB-
dependent genes within our model. Interestingly, mice banded for longer than 4 weeks had
decreased expression of Birc3, Bcl2, and MMP-9. Myocardial apoptosis has been
demonstrated in failing hearts and this was associated with nearly 2-fold elevation in Bcl2
expression with stable Bax expression [30]. Others have not only seen this level of apoptosis
but have seen increased levels of Bcl2 expression in failing hearts [31]. Little data exists
regarding expression of the anti-apoptotic protein Birc3 and heart failure. Nevertheless one
could surmise that changes in the balance between pro- and anti-apoptotic signals could
transition a decompensated heart from one that is potentially recoverable to one that is
irreversibly failed. Similarly, the literature regarding expression of MMPs with heart failure
is conflicting. While many have demonstrated upregulation of MMPs [32], others have more
recently demonstrated MMP-9 downregulation (with stable, elevated levels of TIMP-1) in
hearts from transplant recipients [33]. More relevant to our model of pressure-overload and
relief, patients with worsening levels of systolic function with aortic stenosis receiving aortic
valve replacement had more robust expression of both MMP-2 and -9 [34]. As with
apoptosis, we could construct a paradigm that MMP expression is upregulated during the
progression of heart failure, and that its downregulation may alter the balance between
proteins favoring matrix production and breakdown, thus making a heart no longer capable
of recovery. While each of these hypotheses remains to be tested, the current data serve to
validate our model as a tool to dissect mechanistic points of no return for the failing heart.
Finally, we recognize that we have not identified “the answer” for myocardial recovery. Our
genomic screening has identified patterns of expression that validate the functional
differences in our respective groups and provide a source for deductive and inductive
approaches to manipulating the recovery process. Only one group, to the best of our
knowledge, has inductively extended a single gene observation mechanistically [35]. That
said, the system of remodeling is quite redundant, and manipulation of a single gene will
quite likely not provide clinicians a magic bullet.
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Conclusions and clinical implications
Much attention, both experimentally and clinical, has focused on the issues related to the
development and progression of LVH and HF. This linear approach suggests that variables
can be identified to predict which patients will transition from a compensated to
decompensated state. Thus, interventions are aimed at halting the progression of the disease.
In allegoric terms, physicians are trying to identify the edge of the cliff that the patient needs
to avoid. This report and model system proposes a different paradigm by attempting to
identify the factors that transition a decompensated heart to one that is compensated (Figure
7). Preventive therapy is laudable, but hospitalizations for advanced heart failure are related
to patients that are decompensated. Extending the metaphor, we must presume that patients
will fall off the cliff, even if you know where it is. The question then becomes, how far can
that patient fall and still climb up and must the patient take a different path to recover?
Although an experimental mouse model, this approach allows the temporal and mechanistic
characterization of a practical and potentially high-throughput model to study the “point of
no return” for the failing heart. Furthermore, we identify a distinct gene expression profile
for the recovery of the failing heart. Finally, in addition to providing mechanistic targets for
the study of reverse remodeling, this model establishes a template for testing therapies
aimed at myocardial recovery.
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Experimental design and animal groupings. To determine the physiologic and genomic
profiles in compensated, decompensated, and recovered hypertrophic hearts, mice
underwent trans-aortic constriction (TAC) at 8 weeks of age for 3, 4, or 6 weeks. A subset of
these animals underwent band removal (debanding) for 1 week prior to sacrifice (3, 4, and 6
week debanded groups).
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Physiologic Characteristics of Band and Deband Animals. A. Hemodynamic parameters
obtained from in-situ left ventricular catheterization (n=4–5 for each Band and Deband
group). B. Pressure-volume loops for the respective groups. *p<0.05 compared to the Band
group within that time-period. †p<0.05 vs 3 week banded animal. (HW/BW: heart
weight:body weight; HR: heart rate; EF: Ejection Fraction; ESP: End-Systolic Pressure;
EDV: End-Diastolic Pressure).
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Hypertrophic gene markers. Real-time PCR (relative to 18S expression) from left-
ventricular apices at each Band (B) and Deband (DB) timepoint (n=4–5 for each groups).
βMHC, beta myosin heavy chain; ACTA-1, skeletal muscle alpha1-actin; Col1, collagen
type 1 alpha 1 (COL1a1); BNP – brain natriuretic peptide. *p<0.05 debanded versus
respective banded group at same time point; †p<0.05 6 week banded versus 3 week banded
animals.
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Genomic stages in the progression and regression of hypertrophic heart failure as depicted
by Venn diagrams. A. Microarray analysis reflecting the differences between stages of heart
failure progression compared animals banded for either 3 (compensated), 4
(decompensated), or 6 (failed) weeks. B. Microarray analysis reflecting the differences in
gene expression following pressure-relief in animals previously banded for either 3, 4, or 6
weeks. C. Microarray analysis comparing differences in gene expression between each
physiologic category. All analyses performed with a MFC > 1.5 and p<0.05.
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Cluster analysis, pathways and transcription factors in the progression of heart failure and in
the respective stages of recovery. Genes upregulated (up) or downregulated (down) at a
specific physiologic point in banded groups (A) or debanded groups (B) were run through
the Molecular Signatures Database (MSigDB) to determine the five most significant
genomic pathways and transcription factors within a particular physiologic stage. MFC>1.5,
p<0.05.
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Apoptotic and fibrotic gene markers. Real-time PCR (relative to 18S expression) from left-
ventricular apices at each Band (B) and Deband (DB) timepoint (n=4–5 for each groups).
*p<0.05, debanded versus respective banded group at same time point; †p<0.05, 6 week
banded versus 4 week banded animals.
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Murine model depicting physiologic phase-dependent myocardial failure and recovery.
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